Department Of Medicine 12
551. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
552. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
553. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
554. The burden of cardiovascular events according to cardiovascular risk profile in adults from high-income, middle-income, and low-income countries (PURE): a cohort study
555. Cross-cultural adaptation and psychometric evaluation of the Chinese version of Hospital Culture of Nursing Research Scale (CHCNRS): a translation and validation study
556. Evaluation of clinical research priorities in Asian intensive care units (ERA-ICU)
557. Association of LRRK2 p.A419V with Parkinson’s Disease in East Asians and analysis of age at onset
558. Association of LRRK2 p.A419V with Parkinson’s Disease in East Asians and analysis of age at onset
559. Association of LRRK2 p.A419V with Parkinson’s Disease in East Asians and analysis of age at onset
560. Current and emerging medical treatment options for corneal persistent epithelial defects
561. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
562. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
563. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
564. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
565. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
566. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21)
567. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21)
568. Association of Working Status with Clinical Pregnancy and Miscarriage among Women undergoing In Vitro Fertilization: Single-Centre Cross-Sectional Study
569. Candidate protein biomarkers in chronic kidney disease: a proteomics study
570. Tubular toxicity of proteinuria and the progression of chronic kidney disease
571. Urinary Proteomic Shifts over Time and Their Associations with eGFR Decline in Chronic Kidney Disease
572. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
573. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
574. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
575. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
576. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
577. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
578. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
579. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
580. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
581. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
582. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
583. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
584. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
585. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
586. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
587. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
588. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
589. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
590. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
591. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
592. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
593. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
594. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
595. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
596. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
597. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
598. Comparative Analysis of Regional Mortality Rates and Causes in the Turkistan and Other Regions of Kazakhstan: Data from Unified National Electronic Healthcare System 2018-2023
599. Forecasting the future burden of major diseases in Kazakhstan using global burden of disease and time series models (ARIMA, Prophet, LSTM), 2019-2032
600. Understanding the impact of endometriosis on women’s life: an integrative review of systematic reviews
1 10 11 12 13 14 24